Evaluation and Implementation of Biocompatible Methods for the Cross-linking of Plasma Proteins

Research output: Contribution to journalArticleResearchpeer review

Authors

  • Tom Bode
  • Kai Höltje
  • Sara Leal-Marin
  • Marc Müller
  • Birgit Glasmacher

Research Organisations

View graph of relations

Details

Original languageEnglish
Pages (from-to)187-190
Number of pages4
JournalCurrent Directions in Biomedical Engineering
Volume7
Issue number2
Publication statusPublished - 9 Oct 2021

Abstract

Autologous plasma proteins can be used to fabricate patient specific cardiovascular implants but need to be cross-linked to increase their mechanical strength and reduce water solubility. Glutaraldehyde is the state-of-The-Art solution but its reaction products have been shown to be cytotoxic and pro-inflammatory. In this work, it has been shown, that cross-linking of plasma proteins with biocompatible alternatives to glutaraldehyde is possible. This was achieved by identifying four candidate substances (thrombin, transglutaminase, genipin, EDC) from current literature and investigating their ability to cross-link porcine plasma proteins in vitro. The degree of crosslinking was examined using calorimetric (DSC) and spectroscopic (FTIR, Raman) methods, mapping the influence of cross-linking on the denaturation temperature and primary amino-group content of the proteins. It could be shown that thrombin, genipin and EDC are able to cross-link plasma proteins to a satisfactory degree and thus represent useful alternatives to glutaraldehyde. Transglutaminase, on the other hand, could not sufficiently cross-link the plasma proteins and was therefore ruled out as an alternative.

Keywords

    biocompatible crosslinking, blood plasma, cardiovascular implants, EDC, genipin, glutaraldehyde, proteins, thrombin, transglutaminase

ASJC Scopus subject areas

Cite this

Evaluation and Implementation of Biocompatible Methods for the Cross-linking of Plasma Proteins. / Bode, Tom; Höltje, Kai; Leal-Marin, Sara et al.
In: Current Directions in Biomedical Engineering, Vol. 7, No. 2, 09.10.2021, p. 187-190.

Research output: Contribution to journalArticleResearchpeer review

Bode, T, Höltje, K, Leal-Marin, S, Müller, M & Glasmacher, B 2021, 'Evaluation and Implementation of Biocompatible Methods for the Cross-linking of Plasma Proteins', Current Directions in Biomedical Engineering, vol. 7, no. 2, pp. 187-190. https://doi.org/10.1515/cdbme-2021-2048
Bode, T., Höltje, K., Leal-Marin, S., Müller, M., & Glasmacher, B. (2021). Evaluation and Implementation of Biocompatible Methods for the Cross-linking of Plasma Proteins. Current Directions in Biomedical Engineering, 7(2), 187-190. https://doi.org/10.1515/cdbme-2021-2048
Bode T, Höltje K, Leal-Marin S, Müller M, Glasmacher B. Evaluation and Implementation of Biocompatible Methods for the Cross-linking of Plasma Proteins. Current Directions in Biomedical Engineering. 2021 Oct 9;7(2):187-190. doi: 10.1515/cdbme-2021-2048
Bode, Tom ; Höltje, Kai ; Leal-Marin, Sara et al. / Evaluation and Implementation of Biocompatible Methods for the Cross-linking of Plasma Proteins. In: Current Directions in Biomedical Engineering. 2021 ; Vol. 7, No. 2. pp. 187-190.
Download
@article{367568527e064cde91c143420b4384bd,
title = "Evaluation and Implementation of Biocompatible Methods for the Cross-linking of Plasma Proteins",
abstract = "Autologous plasma proteins can be used to fabricate patient specific cardiovascular implants but need to be cross-linked to increase their mechanical strength and reduce water solubility. Glutaraldehyde is the state-of-The-Art solution but its reaction products have been shown to be cytotoxic and pro-inflammatory. In this work, it has been shown, that cross-linking of plasma proteins with biocompatible alternatives to glutaraldehyde is possible. This was achieved by identifying four candidate substances (thrombin, transglutaminase, genipin, EDC) from current literature and investigating their ability to cross-link porcine plasma proteins in vitro. The degree of crosslinking was examined using calorimetric (DSC) and spectroscopic (FTIR, Raman) methods, mapping the influence of cross-linking on the denaturation temperature and primary amino-group content of the proteins. It could be shown that thrombin, genipin and EDC are able to cross-link plasma proteins to a satisfactory degree and thus represent useful alternatives to glutaraldehyde. Transglutaminase, on the other hand, could not sufficiently cross-link the plasma proteins and was therefore ruled out as an alternative. ",
keywords = "biocompatible crosslinking, blood plasma, cardiovascular implants, EDC, genipin, glutaraldehyde, proteins, thrombin, transglutaminase",
author = "Tom Bode and Kai H{\"o}ltje and Sara Leal-Marin and Marc M{\"u}ller and Birgit Glasmacher",
year = "2021",
month = oct,
day = "9",
doi = "10.1515/cdbme-2021-2048",
language = "English",
volume = "7",
pages = "187--190",
number = "2",

}

Download

TY - JOUR

T1 - Evaluation and Implementation of Biocompatible Methods for the Cross-linking of Plasma Proteins

AU - Bode, Tom

AU - Höltje, Kai

AU - Leal-Marin, Sara

AU - Müller, Marc

AU - Glasmacher, Birgit

PY - 2021/10/9

Y1 - 2021/10/9

N2 - Autologous plasma proteins can be used to fabricate patient specific cardiovascular implants but need to be cross-linked to increase their mechanical strength and reduce water solubility. Glutaraldehyde is the state-of-The-Art solution but its reaction products have been shown to be cytotoxic and pro-inflammatory. In this work, it has been shown, that cross-linking of plasma proteins with biocompatible alternatives to glutaraldehyde is possible. This was achieved by identifying four candidate substances (thrombin, transglutaminase, genipin, EDC) from current literature and investigating their ability to cross-link porcine plasma proteins in vitro. The degree of crosslinking was examined using calorimetric (DSC) and spectroscopic (FTIR, Raman) methods, mapping the influence of cross-linking on the denaturation temperature and primary amino-group content of the proteins. It could be shown that thrombin, genipin and EDC are able to cross-link plasma proteins to a satisfactory degree and thus represent useful alternatives to glutaraldehyde. Transglutaminase, on the other hand, could not sufficiently cross-link the plasma proteins and was therefore ruled out as an alternative.

AB - Autologous plasma proteins can be used to fabricate patient specific cardiovascular implants but need to be cross-linked to increase their mechanical strength and reduce water solubility. Glutaraldehyde is the state-of-The-Art solution but its reaction products have been shown to be cytotoxic and pro-inflammatory. In this work, it has been shown, that cross-linking of plasma proteins with biocompatible alternatives to glutaraldehyde is possible. This was achieved by identifying four candidate substances (thrombin, transglutaminase, genipin, EDC) from current literature and investigating their ability to cross-link porcine plasma proteins in vitro. The degree of crosslinking was examined using calorimetric (DSC) and spectroscopic (FTIR, Raman) methods, mapping the influence of cross-linking on the denaturation temperature and primary amino-group content of the proteins. It could be shown that thrombin, genipin and EDC are able to cross-link plasma proteins to a satisfactory degree and thus represent useful alternatives to glutaraldehyde. Transglutaminase, on the other hand, could not sufficiently cross-link the plasma proteins and was therefore ruled out as an alternative.

KW - biocompatible crosslinking

KW - blood plasma

KW - cardiovascular implants

KW - EDC

KW - genipin

KW - glutaraldehyde

KW - proteins

KW - thrombin

KW - transglutaminase

UR - http://www.scopus.com/inward/record.url?scp=85121846240&partnerID=8YFLogxK

U2 - 10.1515/cdbme-2021-2048

DO - 10.1515/cdbme-2021-2048

M3 - Article

AN - SCOPUS:85121846240

VL - 7

SP - 187

EP - 190

JO - Current Directions in Biomedical Engineering

JF - Current Directions in Biomedical Engineering

IS - 2

ER -